Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 306 participants.
Also called NCT04686643
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 306 participants
- Registry
-
NCT04686643
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04686643. Randomized; double masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- AGSAVI
- Intervention (Drug)
- AGLS
- Lead sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Record details
- Record id
cardio:ct-nct04686643- Content hash
2afba1dca4ffdfad4a0daed57eab9297039ecafc1723561bd8c40235acb796d3